Vallon Pharmaceuticals Inc. (VLON)
$8.59
$-351.42
(-97.62%)
As on 24-Apr-2023 09:30EDT
Market cap
$5 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-3 Mln
-
ROE
-1.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
13,482,300
5 Years Aggregate
CFO
$-24.41 Mln
EBITDA
$-27.78 Mln
Net Profit
$-29.66 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vallon Pharmaceuticals (VLON)
| -1.3 | -30.2 | -0.6 | -87.4 | -- | -- | -- |
|
BSE Sensex*
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
|---|---|
|
Vallon Pharmaceuticals (VLON)
| -95.2 |
|
S&P Small-Cap 600
| -17.4 |
|
BSE Sensex
| 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Vallon Pharmaceuticals (VLON)
As of April 21, 2023, Vallon Pharmaceuticals, Inc. was acquired by GRI Bio, Inc., in a reverse merger transaction. Vallon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel... medications for central nervous system disorders with a focus on abuse-deterrent medications. The company's lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania. Read more
-
CEO, Pres & Director
Mr. David C. Baker
-
CEO, Pres & Director
Mr. David C. Baker
-
Headquarters
Philadelphia, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vallon Pharmaceuticals (VLON)
What is the current share price of Vallon Pharmaceuticals Inc (VLON) Today?
The share price of Vallon Pharmaceuticals Inc (VLON) is $8.59 (NASDAQ) as of 24-Apr-2023 09:30 EDT. Vallon Pharmaceuticals Inc (VLON) has given a return of -87.39% in the last 1 years.
What is the current PB & PE ratio of Vallon Pharmaceuticals Inc (VLON)?
Since, TTM earnings of Vallon Pharmaceuticals Inc (VLON) is negative, P/E ratio is not available.
The P/B ratio of Vallon Pharmaceuticals Inc (VLON) is 0.84 times as on 24-Apr-2023, a 79 discount to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.41
|
1.26
|
|
2021
|
-4.34
|
7.00
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
What is the 52 Week High and Low of Vallon Pharmaceuticals Inc (VLON)?
The 52-week high and low of Vallon Pharmaceuticals Inc (VLON) are Rs -- and Rs -- as of 22-May-2026.
What is the market cap of Vallon Pharmaceuticals Inc (VLON)?
Vallon Pharmaceuticals Inc (VLON) has a market capitalisation of $ 5 Mln as on 24-Apr-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Vallon Pharmaceuticals Inc (VLON)?
Before investing in Vallon Pharmaceuticals Inc (VLON), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.